South Africa Shortlists Local Firms to Produce Lenacapavir HIV Prevention Shot

South Africa lenacapavir manufacturing has taken a decisive step forward with the completion of an initial domestic review that shortlisted local firms for the long-acting HIV prevention agent. This development marks progress in a sustained national strategy to secure voluntary licensing deals, allowing companies to import active pharmaceutical ingredients, finalize formulations, and eventually produce the full product for both domestic needs and broader regional distribution.

South Africa Lenacapavir Manufacturing Evaluation Process

Independent evaluation committees assessed proposals using a staged framework that matched companies to specific segments of the production chain rather than demanding immediate full synthesis of the active ingredient. This method respected existing local infrastructure while meeting the originator’s technical standards from earlier licensing agreements. The shortlist now moves to the originator for detailed verification, including site visits expected to last three to six months.

Patient Preferences and Supply Chain Improvements

Data from 360 public clinics across six provinces show strong uptake of the six-monthly injection among patients offered a choice over daily oral pre-exposure prophylaxis. Earlier 2024 voluntary licences had excluded South African manufacturers because of active pharmaceutical ingredient rules, prompting the current structured assessment to address that limitation directly. Successful technology transfer would enable generic supply for both national programs and Southern African Development Community markets.

Ad

Regional Impact of South Africa Lenacapavir Manufacturing

Completion of the originator review could lower reliance on external donor supplies while building local manufacturing capacity and creating skilled jobs. These changes would support more stable pricing and wider prevention coverage without ongoing external funding. Health economics assessments are already factoring in the long-term sustainability gains once final licensing decisions are confirmed. The announcements, shared during the recent AIDS2026 conference, underscore South Africa’s commitment to scaling access through domestic production capabilities. This aligns with HIV Prevention Access Strategies Through Collaborative Partnerships in South Africa and Gilead’s Lenacapavir Access Strategy in Resource-Limited Countries, while echoing calls in UNAIDS Urges Greater Access for Gilead’s Lenacapavir for expanded affordability.